Mobile website
Archive > Volume 22 Issue 6 > 2015,22(6):760-764. DOI:10.3872/j.issn.1007-385X.2015.06.014 Prev Next
Clinical Research
Clinical effects of the oxaliplatin-based chemotherapy regimen combined with DC-CIK cells on advanced primary liver carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To assess the clinical efficacy and safety of the combined therapy with oxaliplatin (OXA)-based regimen and DC-CIK (dendritic cells and cytokine-induced killer) cells for the treatment of advanced primary liver carcinoma.Methods：A retrospective analysis was carried out for 11 patients with advanced primary liver carcinoma enrolled into the Department of Biotherapy of Eastern Hepatobiliary Surgery Hospital from Jan. 2013 to Jun. 2015. All these patients received FOLFOX4 (OXA+calcium folinatc \[CF\]+5-fluorouracil\[5-FU\]）or GEMOX (gemcitabine\[GEM\]+OXA) chemotherapy. After 2-3 days of chemotherapy, DC-CIK cells immune therapy was administrated. Disease control rate(DCR), median time to tumor progression (mTTP), median overall survival (mOS), and adverse effects were recorded. Results：Among the 11 patients，no one had CR，2 had PR, 5 had SD, and 4 had PD. The response rate and disease control rate were 2/11 and 7/11 respectively. The mTTP and mOS were 4.1 months and 11.3 months. The major side effects were mild myelosuppression，gastrointestinal reaction and peripheral nerve toxicity, which were manageable with symptomatic treatments. Conclusion: For the treatment of advanced primary liver carcinoma, the combined therapy with oxaliplatin-based regimen and DC-CIK cells is effective, and its adverse effects are mild and well-tolerated, indicating that the therapy deserves further evaluation in more clinical trials with more patients.
Keywords:
Project Supported:
Project supported by the Mayor National Science and Technology Project of China（No.2013ZX10002-010-007）
Clc Number:
